Cefdinir
Brand names: Cefdinir
Part of: Common antibiotics
At a glance
- Medicare prescriptions, 2024
- 1,631,613
- Medicare drug cost
- $24.9M
- Average cost per prescription
- $15.29
- Clinicians who prescribed it
- 55,889
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefdinir capsules and other antibacterial drugs, cefdinir capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Cefdinir capsules are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Adults and Adolescents: Community-Acquired Pneumonia: Caused by Haemophilus influenzae (including β-lactamase producing strains), Haemophilus parainfluenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillinsusceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains) (see CLINICAL STUDIES ). Acute Exacerbations of Chronic Bronchitis: Caused by Haemophilus influenzae (including β-lactamase producing strains), Haemophilus parainfluenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase…
From the FDA-approved prescribing information (label dated October 2025). Full labels on DailyMed (opens in a new tab)
Who prescribes it
- Nurse Practitioners 22.8%
- Family Medicine 21.6%
- Internal Medicine 18.4%
- Physician Assistants 11.7%
- Emergency Medicine 7.9%
- Urology 4.4%
- Hospitalist 4.2%
- ENT (Otolaryngology) 2.2%
- Pulmonology 1.3%
- Infectious Disease 1.1%
- General Practice 0.6%
- Nephrology (Kidney) 0.5%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions rose 44% from 2019 to 2024.
Biggest change by state since 2019
- Massachusetts +145%
- Washington +110%
- Wisconsin +93%
- California +75%
- Nevada +72%
- West Virginia (smallest change) +14%
- Utah (smallest change) +21%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
What it looks like
Pills from 4 makers on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.
Ascend Laboratories, LLC
| Strength | Looks like | Imprint |
|---|---|---|
| 125 mg | yellow powder | |
| 250 mg | yellow powder | |
Lupin Pharmaceuticals, Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 300 mg | purple capsule, 22 mm | LUPIN CEFDINIR |
Pd-Rx Pharmaceuticals, Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 300 mg | turquoise capsule, 21 mm | E99 |
Proficient Rx LP
| Strength | Looks like | Imprint |
|---|---|---|
| 300 mg | turquoise capsule, 21 mm | E99 |
Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.
Industry payments about this drug
No industry payments to clinicians named this drug in 2025.
Recalls and shortages
Not on the FDA drug shortage list.
3 recalls since 2020
- May 2024 · Lupin Pharmaceuticals Inc. · Class II
Defective container: lack of seal integrity. - Apr 2024 · Lupin Pharmaceuticals Inc. · Class II
Presence of foreign substance: Product complaint of foreign material in reconstituted bottle. - Jul 2020 · Lupin Pharmaceuticals Inc. · Class II
Superpotent Drug: Out-of-specification (OOS) result observed in an assay test of retention samples.
Recalls usually affect specific lots from one maker, not every version of a drug. Class I is the most serious; most drug recalls are Class II. FDA recalls (opens in a new tab)
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.